MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
GeoVax Labs Net Income 2011-2026 | GOVX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income GeoVax Labs
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26 M | -14 M | -18.6 M | -2.96 M | -2.37 M | -2.56 M | -2.17 M | -3.27 M | -2.69 M | -2.73 M | -2.28 M | -2.14 M | -2.35 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.14 M | -26 M | -6.47 M |
Quarterly Net Income GeoVax Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.32 M | -5.37 M | -5.36 M | - | -5.82 M | -5.06 M | -5.85 M | - | -8.41 M | -5.93 M | -4.04 M | - | -3.97 M | -2.24 M | -2.43 M | - | -1.95 M | -1.31 M | -1.56 M | - | -571 K | -455 K | -596 K | - | -424 K | -654 K | -701 K | - | -667 K | -637 K | -622 K | - | -589 K | -517 K | -548 K | - | -464 K | -576 K | -1.3 M | -693 K | -620 K | -676 K | -700 K | -924 K | -515 K | -680 K | -700 K | -872 K | -190 K | -526 K | -697 K | -610 K | -297 K | -498 K | -731 K | -1.15 M | -376 K | -211 K | -606 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -190 K | -8.41 M | -1.74 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 1.06 | -0.93 % | $ 5.78 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.82 | -4.85 % | $ 464 M |  Britain |
 |
Adagene
ADAG
|
-33.4 M | $ 1.65 | - | $ 92.9 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.45 | 3.6 % | $ 8.3 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 64.9 | -0.15 % | $ 8.68 B |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Biogen
BIIB
|
1.63 B | $ 187.4 | 0.75 % | $ 27.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-59.6 M | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-36.7 M | $ 1.04 | -2.34 % | $ 142 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 10.74 | -2.1 % | $ 707 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-386 M | $ 23.58 | 2.39 % | $ 18.7 B | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 27.0 | -1.28 % | $ 1.74 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 4.42 | -1.34 % | $ 116 M | France |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 201.94 | -3.26 % | $ 5 B |  Danmark |
 |
BioVie
BIVI
|
-17.5 M | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
10.3 B | $ 99.81 | 0.97 % | $ 27.2 B | Germany |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 27.75 | 0.02 % | $ 1.34 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 4.14 | -3.72 % | $ 9.01 B |  Israel |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-847 M | $ 11.13 | -2.02 % | $ 720 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 633.45 | 3.34 % | $ 48 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.64 | -0.75 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
115 M | $ 94.65 | 0.68 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |